Fusion Pharm Inc (OTCMKTS:FSPM) Investor Securities Class Action Lawsuit 02/17/2017

If you purchased a significant amount of shares of Fusion Pharm Inc (OTCMKTS:FSPM) between March 31, 2012 and September 16, 2016, and / or if you purchased any OTCMKTS:FSPM shares prior to March 2012 and continue to hold any of those shares, you have certain options and for certain investors are short and strict deadlines running. Deadline: April 18, 2017. OTCMKTS:FSPM investors should contact the Shareholders Foundation, Inc.

To have your information reviewed for options and to recieve notifications about this case, please use this form. You may also send an email to mail@shareholdersfoundation.com, or call us at (858) 779-1554.
Company Name(s): 
Fusion Pharm
Case Name: 
Fusion Pharm Shareholder Class Action Lawsuit 02/17/2017
Case Status: 
Lawsuit Filed
Affected Securities
Lawsuit Overview
Type of Lawsuit: 
Shareholder Class Action
Date Filed: 
Class Period Begin: 
Class Period End: 
Court of Filing: 
U.S. District Court for the District of Colorado
Deadline To File for Lead: 

February 17, 2017 (Shareholders Foundation) - An investor in shares of Fusion Pharm Inc (OTCMKTS:FSPM) filed a lawsuit in the U.S. District Court for the District of Colorado over alleged violations of Federal Securities Laws by Fusion Pharm Inc in connection with certain allegedly false and misleading statements made between March 31, 2012 and September 16, 2016.

According to the complaint the plaintiff alleges on behalf of purchasers of FusionPharm Inc (OTCMKTS:FSPM) common shares between March 31, 2012 and September 16, 2016, that the defendants violated Federal Securities Laws. More specifically, the plaintiff claims that between March 31, 2012 and September 16, 2016, the defendants caused the Company to issue materially misleading representations and/or omit material information regarding the Company's purported revenues and sales of its PharmPods during the Class Period

On September 16, 2016, the Securities and Exchange Commission (“SEC”) announced fraud charges against Fusion Pharm Inc and its CEO, Scott M. Dittman, among others, for allegedly misleading investors by recording and trumpeting revenues for purported sales of PharmPods by round-tripping money from illegal stock sales by hidden affiliates.